Sjögren's syndrome (disorder)
TRACTISS: A randomized double blind placebo controlled clinical TRial of anti-B-Cell Therapy In patients with primary Sjögren’s Syndrome
Year Started: 2011
A multi-centre, randomised, double-blind, placebo controlled, phase III trial in patients with primary Sjögren’s syndrome with fatigue, oral dryness. Males and female recruited between 18 and 80 years of age with an AECG diagnosis of Primary Sjögren’s Syndrome. Biological samples (salivary gland tissue & fluids) collected at multiple timepoints (details available on request) over a 48 week follow-up period; please note figures for baseline samples are represented (availability of samples from other timepoints on request). Recruitment status for this study is 136 patients.
- Access:
- Closed to access
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | 0 - 3 months |
Clinical records | 3 - 6 months |
Followup records | 3 - 6 months |
Pathology records | 0 - 3 months |
Physiological/biochemical measurements | 3 - 6 months |
Treatment records | 3 - 6 months |
Unknown
Data not recorded
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
RNA | -60°C to -85°C | N/A | Affected | 11 - 25% | |
Saliva | -60°C to -85°C | N/A | Affected | 11 - 25% | |
Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 11 - 25% |
Systemic lupus erythematosus (disorder)
BHSLE: Sequencing Based Genetic Analysis of Systemic Lupus Erythematosus (SLE)
Year Started: 2015
DNA and clinical information are used to look for similarities and differences between people with SLE and those unaffected by the disease. These data can be used to identify genetic differences that are more common in SLE patients and then ask how these genetic factors affect the immune system and how they influence the nature and severity of the disease. Current recruitment status for this study is 220 patients.
- Access:
- Closed to access
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 3 - 6 months |
Freezer temperature logs | 0 - 3 months |
Donor Ethnicity | 3 - 6 months |
Unknown
Data not recorded
101 - 500 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
DNA | -60°C to -85°C | N/A | Affected | 75% -99% | |
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 51 - 75% | |
Plasma | -60°C to -85°C | N/A | Affected | 75% -99% |
Rheumatoid arthritis (disorder)
IRMA: Investigation of the Role of Microbiota in Arthritic Inflammation in DMARD-naïve Early Arthritis patients
Year Started: 2017
Observational, single site study. There are many reports that strongly suggest that certain bacteria living in the mouth and in the intestines of RA patients may cause and/or worsen RA. The purpose of the observational IRMA study is to identify RA patients who also have periodontitis (inflammation in their gums caused by bacteria) and compare them to healthy individuals. We will compare the presence of bacteria in the mouth with the RA disease activity and severity and investigate whether the presence of periodontitis and certain bacteria are related to the inflammation in joints and severity of RA disease. The long term goal is to determine if treating periodontitis, caused by certain bacteria, may help to improve the outcomes for patients with RA. Current recruitment status for this study is 12 patients.
- Access:
- Closed to access
- Type:
- Disease specific
- Status:
- In progress
- Consent restrictions:
- Xenograft restriction
Associated Data Type | Procurement Timeframe |
---|---|
Clinical records | 3 - 6 months |
Freezer temperature logs | 0 - 3 months |
Pathology records | 3 - 6 months |
Physiological/biochemical measurements | 3 - 6 months |
Treatment records | 3 - 6 months |
Donor Ethnicity | 3 - 6 months |
Unknown
Data not recorded
11 - 100 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
DNA | -60°C to -85°C | N/A | Affected | 75% -99% | |
Faeces | -60°C to -85°C | N/A | Affected | 75% -99% | |
Peripheral blood mononuclear cells (PBMC) | Liquid nitrogen liquid phase | N/A | Affected | 75% -99% | |
Plasma | -60°C to -85°C | N/A | Affected | 75% -99% | |
RNA | -60°C to -85°C | N/A | Affected | 26 - 50% | |
Saliva | -60°C to -85°C | N/A | Affected | 75% -99% | |
Serum | -60°C to -85°C | N/A | Affected | 75% -99% | |
Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Affected | 26 - 50% |
Whole blood | -60°C to -85°C | N/A | Affected | 75% -99% |